Total
0
Shares
Memphasys (ASX:MEM) - Executive Chairman, Alison Coutts
Executive Chairman, Alison Coutts
Source: Memphasys
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Reproduction biotechnology and bio-separations company Memphasys (MEM) completes the maiden sale of Felix
  • The sale was made to Diagens Biotechnology, which is a Chinese company that manufacturers and distributes human reproduction products across China
  • This represents a major milestone for Memphasys as it increases its exposure to the Chinese market, which is the largest IVF market in the world
  • Felix is Memphasys’ novel device that quickly and gently separates high-quality sperm from a sample for use in IVF procedures
  • Memphasys was up 14.3 per cent on the market with shares trading at 12 cents

Reproduction biotechnology and bio-separations company Memphasys (MEM) has completed the maiden sale of Felix.

The sale was made to Diagens Biotechnology, which is a Chinese company that manufactures and distributes human reproduction products across China.

This maiden order is valued at $11,000 and comprises a console and a starter kit of cartridges.

This represents a major milestone for Memphasys as it increases its exposure to the Chinese market, which is the largest IVF market in the world.

Felix is Memphasys’ novel device that quickly and gently separates high-quality sperm from a sample for use in IVF procedures.

While it is initially for use in human IVF processes, it will later be applied for use in animal artificial reproduction.

Felix was developed with global reproductive medicine expert, Professor John Aitken at the University of Newcastle.

Memphasys’ earlier prototype device, the CS10, was proven to work and led to some live human births in previously infertile couples, however, it needed substantial change to be suitable for use in IVF clinics.

Further, Memphasys remains in regular contact with its partners to accelerate the commercialisation of Felix. The company is aiming to execute its first clinical sales in Q4 2021.

Memphasys was up 14.3 per cent on the market, with shares trading at 12 cents at 12:08 pm AEDT.

MEM by the numbers
More From The Market Herald

" RocketBoots (ASX:ROC) lists on ASX after $4.25m IPO

Software company RocketBoots (ROC) has debuted on the ASX today after raising $4.25 million through an initial public offer (IPO).

" Gladiator Resources (ASX:GLA) begins exploration at Minjingu

Zeus Resources, a wholly-owned subsidiary of Gladiator Resources’ (GLA), has begun exploration activities at the Minjingu Uranium Project.
Mineral Commodities (ASX:MRC) - CEO, Jacob Deysel

" Mineral Commodities (ASX:MRC) updates MRE at Tormin Inland Strands

Mineral Commodities (MRC) has updated the mineral resource estimate (MRE) for the Western Strandline at the Tormin Inland Strands deposit in South Africa.

" IODM (ASX:IOD) secures new revenue opportunity from WUBS partnership

Software solution company, IODM (IOD) has received a new revenue opportunity from its existing partnership with Western Union Business Solutions (WUBS).